The global diabetic neuropathy market size was valued at USD 4.7 billion in 2022 and is projected to grow at a CAGR of 8.2% during the forecast period of 2023-2031 to reach a value of USD 9.55 billion by 2031. The market growth can be attributed to the increasing prevalence of diabetes worldwide and the rising awareness about the complications associated with diabetes, including diabetic neuropathy.
The increasing prevalence of diabetes, coupled with the ageing population and rising awareness about diabetic complications, is driving the demand for diabetic neuropathy treatment. Additionally, advancements in treatment options and the development of new therapies are expected to propel market growth. Rapidly rising geriatric population contributes to the growth of the diabetic neuropathy market, as older individuals are more likely to develop diabetes and related complications. The increasing number of older adults worldwide will lead to a higher demand for diabetic neuropathy treatments. Government initiatives to raise awareness about diabetes and its complications, along with the provision of funding for research and development, are expected to bolster the diabetic neuropathy market growth.
Asia Pacific is also expected to be the fastest-growing region in the diabetic neuropathy market, due to the large population base, rapidly increasing prevalence of diabetes, and growing awareness of diabetic complications.
The increasing adoption of novel treatment options, such as monoclonal antibodies and stem cell therapy, along with advancements in diagnostic tools, are expected to further drive the growth of the diabetic neuropathy market in the coming years. However, challenges such as the high cost of treatment and limited access to healthcare services in low- and middle-income countries may hinder market growth to some extent. Efforts are being made to address these barriers and improve access to diabetic neuropathy treatment globally.
Global Diabetic Neuropathy Market: Introduction
Diabetic neuropathy refers to nerve damage caused by diabetes. High blood sugar levels can damage nerves throughout the body, leading to various symptoms, such as numbness, pain, and weakness. Diabetic neuropathy is a common complication of diabetes, affecting up to 50% of people with the disease.The increasing prevalence of diabetes, coupled with the ageing population and rising awareness about diabetic complications, is driving the demand for diabetic neuropathy treatment. Additionally, advancements in treatment options and the development of new therapies are expected to propel market growth. Rapidly rising geriatric population contributes to the growth of the diabetic neuropathy market, as older individuals are more likely to develop diabetes and related complications. The increasing number of older adults worldwide will lead to a higher demand for diabetic neuropathy treatments. Government initiatives to raise awareness about diabetes and its complications, along with the provision of funding for research and development, are expected to bolster the diabetic neuropathy market growth.
Diabetic Neuropathy Epidemiology
According to the International Diabetes Federation, approximately 463 million adults were living with diabetes in 2019, and this number is projected to reach 700 million by 2045. Diabetic neuropathy affects a significant proportion of people with diabetes, with varying degrees of severity. The risk of developing diabetic neuropathy increases with age and the duration of diabetes. Proper diabetes management, including blood sugar control and maintaining a healthy lifestyle, can help prevent or delay the onset of diabetic neuropathy.Diabetic Neuropathy Market Segmentations
The market can be segmented based on type, treatment methods, and major region:Market Breakup by Type
- Peripheral Neuropathy
- Autonomic Neuropathy
- Proximal Neuropathy
- Focal Neuropathy
Market Breakup by Treatment
- Antidepressants
- Anti-seizure Medications
- Anticonvulsants
- Electrical Nerve Stimulation
- Topical Medications
- Others
Market Breakup by Region
North America
- United States of America
- Canada
Europe
- United Kingdom
- Germany
- France
- Italy
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Diabetic Neuropathy Market Analysis
North America currently dominates the global diabetic neuropathy market, owing to factors such as a high prevalence of diabetes, advanced healthcare infrastructure, and increasing awareness about diabetic complications. Europe is also a significant market for diabetic neuropathy treatment, driven by a large population base, government initiatives to address diabetes-related issues, and the presence of key market players in the region.Asia Pacific is also expected to be the fastest-growing region in the diabetic neuropathy market, due to the large population base, rapidly increasing prevalence of diabetes, and growing awareness of diabetic complications.
The increasing adoption of novel treatment options, such as monoclonal antibodies and stem cell therapy, along with advancements in diagnostic tools, are expected to further drive the growth of the diabetic neuropathy market in the coming years. However, challenges such as the high cost of treatment and limited access to healthcare services in low- and middle-income countries may hinder market growth to some extent. Efforts are being made to address these barriers and improve access to diabetic neuropathy treatment globally.
Key Players in the Global Diabetic Neuropathy Market
The report provides a detailed analysis of the key players involved in the diabetic neuropathy market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:- NeuroMetrix, Inc
- Allergan PLC
- Pfizer, Inc
- Eli Lilly and Company
- Novartis AG
- Others
Table of Contents
1 Preface
4 Diabetic Neuropathy Overview
5 Patient Profile
6 Current Scenario Evaluation and Regulatory Framework
7 Challenges and Unmet Needs
8 Global Diabetic Neuropathy Treatment Market
9 North America Diabetic Neuropathy Treatment Market
10 Europe Diabetic Neuropathy Treatment Market
11 Asia Pacific Diabetic Neuropathy Treatment Market
12 Latin America Diabetic Neuropathy Treatment Market
13 Middle East and Africa Diabetic Neuropathy Treatment Market
14 Global Diabetic Neuropathy Treatment Market Dynamics
15 Supplier Landscape
16 Global Diabetic Neuropathy Treatment Market- Drug Distribution Model (Additional Insight)
17 Payment Methods (Additional Insight)
Companies Mentioned
- Novartis AG
- Pfizer Inc.
- Glenmark Pharmaceuticals Ltd.
- Eli Lilly and Company
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson
- GlaxoSmithKline Plc
- Lupin Ltd
- Depomed, Inc
- Astellas Pharma Inc
- Meda Pharma GmBH & Co. KG
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 147 |
| Published | March 2023 |
| Forecast Period | 2023 - 2031 |
| Estimated Market Value ( USD | $ 5.09 Billion |
| Forecasted Market Value ( USD | $ 9.55 Billion |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
Related Reports
Global Diabetic Neuropathy Market Report and Forecast 2023-2031
- Report
- 160 Pages
- Global
From
From
Diabetic Peripheral Neuropathy - Pipeline Insight, 2024
- Clinical Trials
- 50 Pages
- Global
From
From
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
